Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer.

Qionghua Tang,Zhijiang Liang,Yingchun Zhou,Yihui Huang,Osamah Ibrahim Khalaf

doi:10.1155/2022/8542376

Abstract

Objective To investigate the differences in uric acid (UA), interleukin-6 (IL-6), and free prostatic-specific antigen (fPSA)/total prostatic-specific antigen (tPSA) (F/T) between patients with and without prostate cancer (PCa) in order to discover the value of the three indicators in improving PCa diagnostic accuracy. Methods Patients with pathologically diagnosed PCa (PCa group, n = 25), patients with other benign prostate diseases (benign group, n = 25), and men who underwent normal physical examination (control group, n = 25) at the First Affiliated Hospital of Guangzhou University of Chinese Medicine between October 2020 and January 2021 were included. The serum UA, IL-6, and F/T levels of participants in the three groups were measured, and the measured data were statistically analyzed. Results There were statistically significant differences in IL-6 and F/T among the three groups (all P < 0.05), but there were no statistically significant differences in UA (P > 0.05). The area under the receiver operating characteristic (ROC) curve (AUC) for the three indicators was, respectively, as follows: PCa group-benign group 0.5416, 0.6776, and 0.6832; PCa group-control group 0.5432, 0.9536, and 0.9887; and benign group-control group 0.5000, 0.8784, and 0.9456. Logistic regression analysis indicated that IL-6 and F/T were independent predictors of PCa, with AUCs of 0.6776 and 0.6832, respectively, and a combined accuracy of 72.0%. Conclusion These results suggest that IL-6 and F/T have a good detection effect for PCa screening. Compared with the detection of F/T alone, the combined detection of IL-6 and F/T can improve the diagnosis rate of PCa to a certain extent, providing effective guidance for the clinical diagnosis and treatment of patients. The value of UA needs to be further studied, and its feasibility in the diagnosis of PCa needs to be further explored.

Highlights

Prostate cancer (PCa) is the most common urinary system malignancy in elderly men [1]
The differences in IL6 and F/T levels were statistically significant between the PCa group and the benign group, and the differences in IL-6 and F/T levels were statistically significant between the benign group and the control group (P < 0:05)
The results showed when the state variable for the PCa group was 1 and that for the benign group was 0, AUC ðUAÞ = 0:5416, AUC ðIL − 6Þ = 0:6832, and AUC (fPSA/tPSAÞ = 0:6776 (Figure 1(a))

Summary

Introduction

Prostate cancer (PCa) is the most common urinary system malignancy in elderly men [1]. In Western countries, PCa is the third leading cause of cancer death in elderly male patients, second only to lung cancer and bronchia cancer [2]. In China, with the continuous aging of the population and changes in dietary habits, the number of obese individuals and diabetic individuals has increased, and the base of the susceptible population has increased, resulting in a significant increase in the incidence of PCa in recent years [3, 4]. Most patients initially respond to androgen deprivation but eventually develop hormone-refractory PCa, leading to late clinical treatment failure and death [5]. The 5-year survival rate for patients with PCa confined to the capsule can exceed 90% after active and effective treatment, and the 5-year survival rate is only 30% or lower when metastasis occurs [6]. An early, accurate diagnosis and rational treatment are very important for PCa patients

Methods

Results

Conclusion